- 2 years ago
(Adnkronos) - In questo numero:
15mila ricoveri l'anno per virus respiratorio sinciziale, nasce Alleanza per infanzia libera dal virus
Per la Giornata internazionale dei diritti delle donne Aism lancia il progetto “Cambia il finale”
Dolcificanti e corretta alimentazione alleati contro l’obesità
Diabete, Lombardia 1a in Europa ad estendere l’accesso gratuito ai sensori del glucosio a tutti i pazienti
Manifesto per l’Europa di Eli Lilly su accesso a farmaci innovativi e ricerca
Diabete, Lombardia 1a in Europa ad estendere l’accesso gratuito ai sensori del glucosio a tutti i pazienti
Dall’osteopatia nuovo approccio terapeutico personalizzato per dolori muscolari e articolari
Presentato il 2023 di Menarini, dall'ingresso negli Usa all'intelligenza artificiale
Dalla Libera università mediterranea algoritmo per analizzare i costi delle prestazioni sanitarie
15mila ricoveri l'anno per virus respiratorio sinciziale, nasce Alleanza per infanzia libera dal virus
Per la Giornata internazionale dei diritti delle donne Aism lancia il progetto “Cambia il finale”
Dolcificanti e corretta alimentazione alleati contro l’obesità
Diabete, Lombardia 1a in Europa ad estendere l’accesso gratuito ai sensori del glucosio a tutti i pazienti
Manifesto per l’Europa di Eli Lilly su accesso a farmaci innovativi e ricerca
Diabete, Lombardia 1a in Europa ad estendere l’accesso gratuito ai sensori del glucosio a tutti i pazienti
Dall’osteopatia nuovo approccio terapeutico personalizzato per dolori muscolari e articolari
Presentato il 2023 di Menarini, dall'ingresso negli Usa all'intelligenza artificiale
Dalla Libera università mediterranea algoritmo per analizzare i costi delle prestazioni sanitarie
Category
🗞
NewsTranscript
00:00 [MUSIC PLAYING]
00:03 [MUSIC PLAYING]
00:06 [MUSIC PLAYING]
00:09 [SPEAKING ITALIAN]
00:12 [SPEAKING ITALIAN]
00:16 [SPEAKING ITALIAN]
00:19 [SPEAKING ITALIAN]
00:22 [SPEAKING ITALIAN]
00:26 [SPEAKING ITALIAN]
00:29 [SPEAKING ITALIAN]
00:32 [SPEAKING ITALIAN]
00:36 [MUSIC PLAYING]
00:38 [SPEAKING ITALIAN]
00:41, [SPEAKING ITALIAN]
01:11 [MUSIC PLAYING]
01:14 [SPEAKING ITALIAN]
01:17 [SPEAKING ITALIAN]
01:20 [SPEAKING ITALIAN]
01:22 [SPEAKING ITALIAN]
01:25 [SPEAKING ITALIAN]
01:27 [SPEAKING ITALIAN]
01:30 [SPEAKING ITALIAN]
01:32 [SPEAKING ITALIAN]
01:34 [SPEAKING ITALIAN]
02:03 [SPEAKING ITALIAN]
02:32 [SPEAKING ITALIAN]
02:46 [SPEAKING ITALIAN]
02:49 [SPEAKING ITALIAN]
03:19 [SPEAKING ITALIAN]
03:45 [SPEAKING ITALIAN]
04:14 [SPEAKING ITALIAN]
04:19 [SPEAKING ITALIAN]
04:31 [MUSIC PLAYING]
04:35 [SPEAKING ITALIAN]
04:37 [SPEAKING ITALIAN]
05:05 [SPEAKING ITALIAN]
05:08 [SPEAKING ITALIAN]
05:10 [SPEAKING ITALIAN]
05:12 [SPEAKING ITALIAN]
05:41 [SPEAKING ITALIAN]
06:08 [SPEAKING ITALIAN]
06:20 [SPEAKING ITALIAN]
06:41 [SPEAKING ITALIAN]
07:10 [SPEAKING ITALIAN]
07:12 [SPEAKING ITALIAN]
07:14 [SPEAKING ITALIAN]
07:16 [SPEAKING ITALIAN]
07:18 [SPEAKING ITALIAN]
07:20 [SPEAKING ITALIAN]
07:48 [MUSIC PLAYING]
07:50 [MUSIC PLAYING]
07:54 [SPEAKING ITALIAN]
07:56 [SPEAKING ITALIAN]
08:24 [SPEAKING ITALIAN]
08:34 [SPEAKING ITALIAN]
08:52 [SPEAKING ITALIAN]
09:11 [SPEAKING ITALIAN]
09:40 [SPEAKING ITALIAN]
10:09 [MUSIC PLAYING]
10:21 [SPEAKING ITALIAN]
10:22 [SPEAKING ITALIAN]
10:51 [SPEAKING ITALIAN]
10:52 [SPEAKING ITALIAN]
10:55 [SPEAKING ITALIAN]
10:56 [SPEAKING ITALIAN]
10:58 [SPEAKING ITALIAN]
11:00 [SPEAKING ITALIAN]
11:02 [SPEAKING ITALIAN]
11:03 attractiveness of private investments in research, development and drug production.
11:09 It is clear that we, as an industry in the sector, particularly engaged in Italy,
11:13 both in research and development, we expect a system that is ever faster in terms of evaluation,
11:20 price and reimbursability and therefore as a final point the arrival of our innovation to patients who need it the most.
11:29 We expect that, beyond structural reforms, process reforms will be made that will help to democratize,
11:38 simplify and therefore accelerate the arrival of our innovation to the patient's bed.
11:43 We need investors and therefore foreign companies that come and believe in Italy.
11:49 The theme is to make them stay in Italy, to increase the degree of investment that,
11:55 basically, has as a positive effect to prevent our researchers and graduates from going abroad to work,
12:04 if not under free choice and therefore with an individual choice, but above all they tend to strengthen our PIL.
12:10 The challenge for Europe is to increase the attraction of investments in research, development and production in the pharmaceutical field,
12:17 especially in the face of the new challenges brought by the pandemic.
12:21 The health and health issues, in fact, will be decisive also for the next European elections that will take place in June.
12:27 Reducing the time of one year after the approval of the EMA compared to the time of the EIA,
12:36 certainly must be pursued.
12:41 There is a very concrete possibility, that of the start of the European HTA, the JCA.
12:50 It is very important that the EIA has a much closer link with the EMA activity, which has not happened so far.
12:58 In theory, we can know even two years before what happens.
13:03 We can prepare a HTA dossier in those two years, be ready to bring our requirements, our line to Europe
13:16 and avoid not only the EIA year, but also the two years of the regions.
13:22 In Lombardy, all people with diabetes will be able to access glucose monitoring devices with sensors for free.
13:32 To establish this, the new criteria for regional legibility, just issued by the Lombardy Region,
13:37 with which the prescribability is extended in charge of the regional health system,
13:41 will be the use of the new glucose monitoring devices with sensors such as the Abbott Freestyle Libre,
13:46 as well as patients with type 1 diabetes, type 2 diabetes patients in basic insulin therapy
13:52 and, for the first time in Europe, type 2 diabetes patients in oral hypoglycemic therapy for a period of three months.
13:59 We are starting to experiment with the future.
14:01 Here in the Lombardy Region, a region with 587,000 type 2 diabetes patients,
14:07 a great concern for all diabetes patients, one of the first chronic diseases in our country.
14:13 Technology also allows us to reduce health spending,
14:18 because this attention not only improves the patient's life, but also improves regional health spending.
14:25 So, in this direction, we are innovating towards the future with investments aimed at this direction.
14:31 The use of glucose monitoring systems in the blood has a positive impact on clinical success
14:36 and promotes a more active involvement of the patient in the effective management of the pathology,
14:41 as evidenced by the results of the recent study conducted by the Iniguarde Hospital and the Brescia Hospital
14:46 on people with type 2 diabetes in basic insulin therapy or oral therapy who used Abbott's Freestyle Libre 2.
14:53 We have shown that in a population of patients affected by type 2 diabetes or type 2 diabetes in basic insulin therapy,
15:01 the system has been able to reduce the amount of hemoglobin glycated by 0.4%
15:08 and in 6-3 months also a reduction in the rate of hypoglycemia.
15:12 So, a significant improvement in glycemic compensation in a population of patients affected by type 2 diabetes
15:19 is quite frequent, about 1 in 5 diabetic patients have this type of therapy, so a significant result.
15:27 Thanks to the most innovative self-monitoring systems, equipped with sensors capable of transmitting minute by minute
15:32 the data directly to the patient's smartphone without even the need for scanning,
15:37 people with diabetes not only no longer have to point their fingers daily,
15:41 but also have the possibility of easily accessing the data they need to live a healthier life.
15:47 The advantages of the flash or the intermittent sensor, in my opinion, as a patient and as a representative of patients,
15:57 I say that it will be huge, and it will be huge mainly for two factors.
16:03 First, because it makes the person who carries it aware and aware,
16:08 second, because it optimizes metabolic control.
16:13 What are the consequences of the cold?
16:17 Especially in winter, there are many people who have to deal with muscle and joint pain.
16:22 The cold, combined with the increase of humidity, precipitation and the poor physical activity practiced,
16:27 creates a fertile ground for the manifestation or worsening of these musculoskeletal disorders,
16:32 which, according to the Global Burden of Disease, the largest epidemiological and observational study in the world,
16:38 suffer 1.710.000.000 people.
16:42 Muscle contractions, blood flow reduction and joint stiffness are the most common causes
16:46 responsible for the increase of the risk of inflammation and pain.
16:50 To deal with these problems, significant progress has been made,
16:53 with particular attention to the personalization of osteopathy,
16:56 to adapt it to the specific needs of each patient.
16:59 For example, Giordano's equations, a therapeutic and innovative approach,
17:02 today a matter of study of many future professionals in the sector.
17:05 Giordano's idea, after years of experience also in the world of agonistic sport, especially tennis.
17:11 To face these challenges, it is important to adopt conscious and proactive behaviors.
17:15 Personally, I believe in the holistic approach of osteopathic medicine,
17:19 which considers the body as a complex system of muscles, skeletal structures, nerves and internal organs,
17:24 all interconnected with each other.
17:26 Osteopathy is based on manual and non-invasive contact,
17:29 to assess, diagnose and treat patients,
17:32 analyzing the interconnections between the musculoskeletal, vascular and neurological system.
17:37 This global approach to human health offers a complete view of our well-being,
17:41 and can be particularly effective in the treatment of musculoskeletal disorders.
17:46 I have developed an innovative therapeutic approach,
17:48 which is based on a deep evaluation of the patient,
17:50 to identify and solve the dysfunctions of the musculoskeletal system.
17:54 This method has been tested on several patients,
17:57 providing instructions on how to solve specific problems in the various regions of the body.
18:01 It is distinguished by its safety, non-invasiveness
18:04 and safe resolution of dysfunctional problems of the musculoskeletal system.
18:08 Through an approach based on a deep evaluation of the patient,
18:12 precise and targeted manual techniques are used to identify and treat dysfunctions in a specific and personalized way.
18:19 This method not only offers effective results in the relief of muscle and joint pain,
18:24 but also promotes the restoration of body balance in its complex.
18:28 Its non-invasive nature makes it suitable for a wide range of patients,
18:33 guaranteeing a safe and comfortable treatment.
18:36 An approach is described by Giordano himself in the book "The Structural Osteopathy Biographies".
18:40 Osteopathy also offers benefits in the female field,
18:43 and during pregnancy can promote an ideal hormonal balance,
18:47 improve skin brightness and reduce abdominal swelling and lower arches.
18:52 During pregnancy, it can contribute to a more physiological birth
18:55 and eliminate common disorders such as lumbar and cervical diseases.
18:59 In conclusion, I believe that prevention and targeted osteopathic treatment
19:03 can really make a difference in preserving the well-being of our body.
19:07 It is important to take care of our body in a global way,
19:10 considering not only the symptoms but also the underlying causes of our disorders.
19:14 Always remember to listen to your body.
19:22 The data of the Menarini pharmaceutical company,
19:25 which is based in the Tuscan capital,
19:28 were presented in the auditorium of the Chamber of Commerce of Florence in 2023.
19:32 The numbers confirm the solidity of the company,
19:35 which since 2010 has a constant growth and productive establishments in 140 countries.
19:40 The year that brought the United States at an incredible speed
19:44 to be the second country for importance for Menarini,
19:49 we can only be satisfied with this result.
19:53 It was also a year that saw an increase in global quantity,
19:59 so the demand for our drugs increased by more than 9%.
20:04 This is also a testimony of the quality and importance
20:08 that we do every day for patients.
20:11 Among the most interesting news,
20:13 the entry and the establishment also in the pharmaceutical field of artificial intelligence,
20:18 which can be of great help to human intelligence.
20:21 We recently signed an agreement with a company specialized in the research of drugs
20:29 through artificial intelligence.
20:31 Artificial intelligence can be of great help,
20:34 always together with human intelligence,
20:37 in finding the best targets and then on these targets
20:43 find the best molecule able to interact.
20:47 So we always got into the area of oncology,
20:51 always of the breast tumor,
20:53 and this is our first step in this area.
20:57 A methodology, that is set up through an algorithm
21:06 by a team of researchers of the Liberal Mediterranean University in Giuseppe de Gennaro,
21:11 able to determine the cost of the health performance,
21:14 useful to establish the right rate,
21:17 and how much it affects the treatment of a single patient.
21:21 The investigation of the work group, directed by Francesco Albergo,
21:25 was presented to the press in the auditorium of the Ministry of Health in Rome.
21:30 The analysis, started in 2017,
21:33 has monitored about 50 pathologies in 4 hospitals and 2 clinical centers in Puglia.
21:38 So, what is the real cost of the hospital health performance?
21:43 To this day, the real cost of the hospital health performance has never been determined.
21:51 I can appreciate it, but to appreciate it I have to know the costs.
21:55 A few years ago, this important research work was born,
21:59 of the LUM University,
22:01 which had the purpose of determining a methodology,
22:06 able, from the north to the south of Italy,
22:08 and in all hospital structures,
22:10 in the diversity of their organizations,
22:14 to determine exactly how much it costs me.
22:18 The study objects were 4 of the 6 ASLs in Puglia,
22:22 2 polyclinics, 2 ERCs and the hospital Miulli.
22:26 So, an extremely significant champion,
22:28 with almost 50 particularly complex critical pathologies,
22:32 where a real trade union was found,
22:35 basically a thread that manages to combine all the different pathologies
22:43 with a logic in determining their costs.
22:47 And today, thanks to a multinational partner, our university,
22:52 a software has been able to be realized,
22:56 able to determine the costs,
22:58 regardless of the pathology,
23:00 regardless of the department in which it is analyzed,
23:04 with significant and important data.
23:08 Among others, the Health Secretary, Marcello Gemmato,
23:12 who has analyzed the importance of new organizational models.
23:16 The fact of being able to parameterize all with the punctual,
23:21 segmented and in-depth DRGs,
23:23 compared to the health performance,
23:25 obviously helps to make a correct programming,
23:28 helps to optimize the performance of the national public health system,
23:33 above all, helps to create new organizational models.
23:37 The Director of the Department of Health of the Puglia Region, Vito Montanaro,
23:42 explained how the study on the cost analysis was born.
23:46 A few years ago we imagined starting a study
23:50 that could determine the economic components
23:55 of the production of each DRG.
24:01 It is important, especially for the regions of the South,
24:04 to show that the value of DRGs, that is, the value of the rates,
24:09 is not exactly consistent with the production components,
24:14 especially with the prices and costs updated to date.
24:19 This was our latest news.
24:26 To contact us, you can write to salute@dnchronos.com.
24:30 Thank you for following us and see you next time.
24:33 [Music]
24:47 you
Comments